Lori Infinger
Family · North Charleston, SCNPI 1245233444
Payments from drug & device makers
Across 15 payments — averaging $68.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vifor Pharma, Inc.$243
- GSK$180
- Boston Scientific$174
- Cormedix Inc.$104
- Calliditas Therapeutics US Inc.$104
- Ardelyx, Inc.$70
- plus $150 from 3 others
What the payments were for
- Food & beverage$98696%
- Education$394%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vifor Pharma, Inc. | 3 | $243 |
| GSK | 3 | $180 |
| Boston Scientific | 2 | $174 |
| Cormedix Inc. | 1 | $104 |
| Calliditas Therapeutics US Inc. | 1 | $104 |
| Ardelyx, Inc. | 1 | $70 |
| Novartis | 1 | $60 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $47 |
| Amgen | 2 | $43 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korsuva$123
- DefenCath$104
- TARPEYO$104
- WATCHMAN FLX$100
How this compares
$1,025 in reported general payments places this provider in the 65th percentile of 3,248 family providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 30 | $81,588 |
| AuryxiaFerric Citrate | 17 | $27,478 |
| Sevelamer Carbonate | 78 | $21,841 |
| VeltassaPatiromer Calcium Sorbitex | 11 | $13,445 |
| LokelmaSodium Zirconium Cyclosilicate | 18 | $13,278 |
| Calcium Acetate | 68 | $6,753 |
| Midodrine Hcl | 38 | $2,706 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 61 | $974 |
| Hydralazine Hcl | 52 | $709 |
| Nifedipine ErNifedipine | 19 | $593 |
| Ondansetron Hcl | 15 | $528 |
| Amlodipine Besylate | 54 | $387 |
| Losartan Potassium | 32 | $372 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 12 | $354 |
| Doxazosin Mesylate | 25 | $351 |
Paid to pharmacies, not to this prescriber.
Other family in North Charleston
- Tina WithrowNorth Charleston$19K
- Alison FogartyGreenville$2M
- Sara ChristieGreenville$229K
- Kara Cooper GilmerAnderson$127K
- Jessica BellEasley$96K
- Carrie HendersonGreenville$91K
- Sarah ValerioGreer$76K
- Mary WilliamsColumbia$67K
- Michelle StrongGreenville$55K
- Karen McKerihanSummerville$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.